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Abstract 
Trazodone is a drug that was introduced in the clinic almost 40 years ago. It is licensed 
to treat depression, but it is also commonly used off-label to treat insomnia. A recent 
study shows that it could be promising in preventing neurodegeneration in mice and 
clinical trials to assess its possible beneficial effects in dementia and Alzheimer’s 
disease are expected to start soon in humans. In this study we describe the dose-
dependent pharmacology of trazodone by carrying out a pharmacokinetic simulation 
aiming to predict the brain concentrations of trazodone for different drug dosing 
regimens and calculating occupancy for 28 different targets for which published 
trazodone binding data are available. Our study indicated that low doses of trazodone 
(typically 50 mg daily) should suffice to block specific receptors responsible for the 
hypnotic effect and for protective effect against neuroinflamation and 
neurodegenation that could be beneficial in dementia. Higher doses are required for 
an antidepressant effect. The occupancy of specific receptors at therapeutic doses also 
explains peculiar side effects reported by trazodone (e.g. dry-mouth, priapism and 
hypotension). 
Keywords:
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Introduction 
Trazodone was introduced in the early 1970s (Khouzam, 2017). Currently it is only 
licensed for treating depression, but it is commonly used off-label for other conditions, 
mainly to treat insomnia (Wong et al., 2017). Stahl reported that even if “trazodone 
was never officially approved as a hypnotic, nor marketed as a hypnotic, it 
nevertheless accounts for up to half of all prescriptions for hypnotics” (Stahl, 2013). 
Trazodone is also used off-licence to treat other conditions such as the behavioural 
and psychological symptoms of dementia in Alzheimer’s disease (AD) (Lopez-Pousa et 
al., 2008) and in fronto-temporal dementia (Lebert et al., 2004). In animals, it has 
previously shown benefit in models of Huntington’s disease (Kumar et al., 2011) by 
protecting neuronal-like cells from inflammatory insult (Daniele et al., 2015) and to 
prevent neurodegeneration (in mice) (Halliday et al., 2017). The latter study in 
particular provided promising results and clinical trials are expected to start soon to 
assess trazodone’s protective effect in dementia and AD. 
 
Given that trazodone is only licensed for depression, there is need to know the dose 
required for treating the variety of other conditions for which it is used and the 
pharmacological mechanism of its action.  The pharmacological activity of trazodone is 
dependent on the dose given and Stahl has tried to rationalise the dose-dependent 
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pharmacological effects of trazodone by discussing occupancy to different targets 
calculated using predicted plasma concentration of trazodone administered orally in 
different drug dosing regimens (Stahl, 2009).  
 
In the present study we wanted to improve the understanding of the mechanism of 
action of trazodone described in Stahl’s analysis by (i) calculating receptor occupancy 
using brain concentration rather than the plasma level of trazodone; and (ii) 
considering a larger number of pharmacological targets.  We also aimed to validate the 
use of a software called Berkley Madonna (BM) (Krause and Lowe, 2014; Berkeley 
Madonna, 2016).  Thus we wanted to try to reproduce the experimental 
pharmacokinetic profile (PK) of trazodone and compare the performance of the model 
produced by BM with the methodology used by Stahl and co-workers (Lemaire et al., 
2009; Stahl, 2009). Finally, we aimed to suggest a pharmacodynamic mechanism by 
which trazodone is able to reduce the levels of activating transcription factor 4 (ATF4) 
(a key mechanism in slowing neurodegeneration) without affecting the level of 
phosphorylated eukaryotic initiation factor 2α (eIF2α-P) as reported by Halliday and 
co-workers (Halliday et al., 2017).  
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With the prediction of occupancies we also suggest a likely dose of trazodone that 
could be used in future clinical trials to evaluate its possible protective effect in 
dementia and AD. 
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Method 
A two-compartment pharmacokinetic (PK) model was developed using Berkley 
Madonna (BM) beta version 9.0.123 (Berkeley Madonna, 2016; Krause and Lowe, 
2014) in order to predict the pharmacokinetic profile of trazodone administered orally. 
A simple representation of the model developed in BM is shown in Figure 1 (the 
description of the compartments is similar to the structure of the model published by 
Lemaire and co-workers (Lemaire et al., 2009)). 
 
Figure 1.  The 2-compartment pharmacokinetic (PK) model developed for trazodone 
using BM. 
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Two differential equations were used for the modeling in BM: the first describes the 
absorption from the gastro-intestinal (GI) tract: 
 
d/dt(GI-tract) = input - Ka *(GI-tract) 
 
where “input” accounts for the amount of trazodone taken orally in a specific time 
interval (24 hours in this study) and Ka is the constant of absorption from the GI tract to 
the central compartment. The amount of drug considered in the input function is the 
dose of trazodone multiplied by its bioavailability (F=0.65) (Truven Health Analytics, 
2013) in order to account for the fraction of the administered dose that reaches the 
systemic circulation as unchanged drug. The “input” administration by the GI tract is 
modeled by the pulse function in BM (Krause and Lowe, 2014). 
 
The second equation describes the distribution in the central compartment A1 and in 
the peripheral compartment: 
 
d/dt(A1)= + Ka*(GI-tract)– Ke*A1 –K12*A1 +K21*A2 
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where Ke is the constant of elimination from the central compartment A1 (this is also 
equal to ln2 divided by the half life of elimination of trazodone – 7.3 hours in humans 
(Obach et al., 2008) thus a Ke of 0.095 h-1 assuming linear PK and first order 
elimination). K12 and K21 are the constants for the first order distributions of trazodone 
between the central and peripheral compartment. All the parameters of the model, 
the central (A1) and peripheral compartment (A2) are shown in Figure 1.  
 
In order to solve the differential equation, the integration method Runge–Kutta  4  in 
BM was used; the time intervals to be used in the numerical solving of the differential 
equation system was 0.02 hours. 
 
To create the trazodone PK model, the curve fit and sliders functions in BM were used 
for the estimation of Ka, K12 and K21 by modelling the experimental plasma 
concentration curve of a specific dose of trazodone published in the literature. 
 
WebPlotDigitizer (Ankit Rohatgi, 2016) was used to extract the experimental data 
points of the trazodone plasma concentrations versus time measured after an oral 
administration of 50 mg of trazodone given to 6 individuals (having a mean weight of 
70 Kg) from the plot in Figure 2 published  by Gammans and co-workers (Gammans et 
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al., 1984). These points were imported as an external dataset in BM and this was used 
as a template to fit the PK model using the “curve fit” tool in BM by exploring different 
combination of Ka, K12 and k21 (Ke was instead set as 0.095 h-1 as explained in the 
methods section). BM allows also adjusting each parameter individually to better fit 
the curve using the sliders function. 
 
The central compartment was approximated to represent the blood circulation 
compartment where trazodone is distributed as in the report published by Lemaire 
and co-workers (Lemaire et al., 2009) . In order to estimate the plasma concentration, 
the amount of trazodone in the central compartment was divided by the volume of 
distribution of trazodone in humans ( 36.4 L for a 70 Kg individual (Obach et al., 2008)). 
The human brain concentration was estimated considering  the plasma/brain ratio 
measured experimentally in mice (the experimental Cu,plasma/Cu,brain ratio reported in 
mice is 1.8 (Maurer et al., 2005) in this study we assumed that the plasma/brain ratio 
in humans is the same as the ratio measured in mice) 
 
Different doses of trazodone were simulated (50, 100, 150 daily and 100 mg tds) and 
the integration interval was set as 24 hours. 
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The E max sigmoid model (Rosenbaum, 2011) was used to calculate the receptor 
occupancy. The formula is 
 
[trazodone]brain/(Ki+[trazodone]brain)  
 
where [trazodone]brain is the brain concentration of trazodone 
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Results  
The experimental plasma concentration curve for trazodone was best modelled with a 
two-compartment pharmacokinetic (PK) model: the parameters for this PK model were 
the following : K12=0.134 h-1; K21=0.0313 h-1; Ka  4.319 h-1; Ke =0.095 h-1. The curve fit 
and sliders tools in BM were used to produce the PK model by fitting the data 
published by Gammans and co-workers (Gammans et al., 1984). The result is shown in 
Figure 2. 
 
Figure 2. PK model fitting in BM. The data points were extracted from Figure 2 
published by Gammans and co-workers (Gammans et al., 1984). The continuous line 
represents the PK fitted curve obtained using BM. 
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This modelling methodology seems suitable in the case of trazodone as can be seen 
with the good fit between the simulated curve produced with our model in BM and the 
experimental plasma values measured by Gammans and co-workers (Gammans et al., 
1984).  This is also in agreement with other studies showing that trazodone follows a 
two-compartment pharmacokinetic model (Lee and Desai, 2007; Lemaire et al., 2009). 
 
The fact that our model shows that the K12 is 4.3 fold higher than K21 suggests that 
trazodone distributes substantially to the peripheral compartment (Figure 2). This was 
expected since trazodone is a basic lipophilic compound, thus this compound is 
predicted to bind to fat tissues and membranes (Schmitt, 2008).   
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The plasma concentration and the brain concentration curves for trazodone 50, 100, 
150 daily and 100 mg tds predicted with BM are shown in Figures 3 and 4 respectively 
 
Figure 3. Plasma concentration curves for trazodone 50, 100, 150 daily and 100 mg tds 
predicted with BM using the 2-compartment model created as described in the 
methods section.  
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Figure 4. Brain concentration curves for trazodone 50, 100, 150 daily and 100 mg tds 
predicted with BM using the 2-compartment model created as described in the 
methods section.  
 
 
The therapeutic (antidepressant) window of trazodone is said to be a plasma level of 
between 0.5 and 1.6 μg/mL whereas toxic effects are expected to be seen when the 
concentration of trazodone is above 4 μg/mL (Schulz and Schmoldt, 2003). The drug 
dosage regimen that best fits this window of plasma concentrations is seen when 
trazodone is given as 100 mg od or tds (Figure  2). When 50 mg od is given, the plasma 
level is for the most part below the therapeutic threshold.  When 150 mg is given the 
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plasma concentrations are within the therapeutic window but approach the upper 
limit of the therapeutic window (Figure 2).   
 
Given that the free plasma/brain ratio is expected to be 1.8 (assuming that the brain 
permeability of trazodone in mice (Maurer et al., 2005) is similar to the brain 
permeability in humans) the brain concentration is expected to be almost half than the 
plasma concentration (as can be seen by comparing Figure 2 and Figure 3). 
 
We calculated the occupancy with the brain concentration using the Emax model 
described in the methods section; in order to calculate the occupancy we needed (i) 
the concentrations of trazodone in the brain for each drug dosage regimen and (ii) the 
binding affinity for the receptor or transporter (published in the literature). These 
values are reported in Table 1 and Table 2. 
 
Table 1 shows the Cmax concentrations in the plasma and brain for the three different 
drug dosage regimens taken from Figure 3 and 4. The brain Cmax concentrations were 
used to calculate the occupancies since the pharmacological actions of trazodone 
originates by binding to the different targets (receptors and transporters) in the brain. 
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Table 1. Cmax trazodone (in μg/mL or mg/L) concentrations predicted in the plasma and 
in the brain after the BM PK simulation of trazodone given as 50 mg od, 100mg od and 
150 mg od. a:value taken from the curves in Figure 2; b: value taken from the curves in 
figure 3. 
Dose Plasma Cmaxa Brain Cmaxb  
50 mg daily 0.76 0.42 
100 mg daily 1.5 0.83 
150 mg daily 2.27 1.26 
 
Table 2 reports the binding affinity of trazodone for key receptors and transporters 
obtained from the literature (Roth and Driscol, 2011).  
 
Table 2. Binding affinities (where data available) of trazodone for different 
transporters and receptors (trazodone is an antagonist/blocker for all the targets in the 
table except for 5-HT1A receptor where it behaves as a partial agonist/agonist). Values 
taken from reference (Roth and Driscol, 2011).  
 
17 
 
Protein Ki (nM)  
SERT 367.3 
NET >10000 
DAT >7000 
5-HT1A(*) 118 
5-HT1B >10000 
5-HT1D 106 
5-HT1E >10000 
5-HT2A 35.8 
5-HT2B 78.4 
5-HT2C 223.9 
5-HT3 >10000 
5-HT5A >10000 
5-HT6 >10000 
5-HT7 1782 
α1A 153 
α1B ND 
α2A 728 
α2B ND 
α2C 155 
β1 >10000 
β2 >10000 
D1 3730 
D2 4142 
D3 ND 
D4 703 
D5 >10000 
H1 220 
H2 3290 
H4 >10000 
mAChRs >10000 
nAChRs >10000 
SERT: serotonin transporter; NET: norepinephrine transporter; DAT: dopamine transporter; 5-HT: 5-
hydroxytryptamine(serotonin) receptors (different subtypes); α: alpha adrenergic receptors (different 
subtypes); β: beta adrenergic receptors (different subtypes); D1-5: dopamine receptors; H: histamine 
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receptors (different subtypes); mAchR muscarinic receptors; nAChRs: nicotinic receptors; ND: not 
determined. (*):Trazodone behaves as agonist/partial agonist for 5-HT1A (Odagaki et al., 2005) 
 
We calculated the occupancy for all the proteins (receptors and transporters) in Table 
2 using the brain concentrations for the three drug dosage regimens in Table 1 and 
reported the results in Table 3. 
 
Table 3. Occupancy calculated with the E max sigmoid model based on the brain 
concentrations Cmax reported in Table 2.  
 
Protein Occupancy  for dose 
of 50 mg daily 
Occupancy for dose of 
100 mg daily 
Occupancy for dose of 
150 mg daily 
SERT 0.75 0.86 0.90 
NET < 0.10 <0.18 <0.25 
DAT < 0.14 <0.24 <0.33 
5-HT1A(*) 0.91 0.95 0.97 
5-HT1B < 0.10 <0.18 <0.25 
5-HT1D 0.91 0.95 0.97 
5-HT1E < 0.10 <0.18 <0.25 
5-HT2A 0.97 0.98 0.99 
5-HT2B 0.94 0.97 0.98 
5-HT2C 0.83 0.91 0.94 
5-HT3 < 0.10 <0.18 <0.25 
5-HT5A < 0.10 <0.18 <0.25 
5-HT6 < 0.10 <0.18 <0.25 
5-HT7 0.39 0.56 0.66 
α1A 0.88 0.94 0.96 
α1B ND ND ND 
α2A 0.61 0.75 0.82 
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α2B ND ND ND 
α2C 0.88 0.94 0.96 
β1 < 0.10 <0.18 <0.25 
β2 <0.10 <0.18 <0.25 
D1 0.23 0.37 0.48 
D2 0.21 0.35 0.45 
D3 ND ND ND 
D4 0.62 0.76 0.83 
D5 < 0.10 <0.18 <0.25 
H1 0.84 0.91 0.94 
H2 0.26 0.40 0.51 
H4 < 0.10 <0.18 <0.25 
mAChRs < 0.10 <0.18 <0.25 
nAChRs < 0.10 <0.18 <0.25 
ND: not determined. (*):Trazodone behaves as agonist/partial agonist for 5-HT1A 
(Odagaki et al., 2005). 
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Discussion 
BM is able to reproduce PK simulations published in the literature 
The plasma concentration curves predicted with BM for the trazodone doses of 50 mg 
od, 100 mg od and 100 tds (in Figure 3) are very similar to the plasma concentration 
curves for the same dosage regimens published by Stahl (Stahl, 2009). This 
demonstrates the strength and reliability of the methodology used in our study and 
validates our PK model created with BM since this produced results very similar to 
published PK data (Lemaire et al., 2009; Stahl, 2009). 
 
Trazodone has a half-life of 7.3 hours (Obach et al., 2008) and it requires frequent 
administrations in order to provide a sustained exposure: the ideal time interval of 
administration for a drug is an interval as close as possible to the half-life of the drug 
administered if the oral IR formulation is given (Rosenbaum, 2011).  Thus for 
trazodone standard release, the ideal oral dosage regimen is three times daily. This can 
be seen in Figure 3 and 4.  In order to provide a better exposure over time during the 
day, a drug dosage regimen such as 100 mg tds should be chosen rather than a once 
daily administration. This fact, in combination with the risk of toxic effect seen when 
the Cmax is reached (especially when high doses are administered) explains why the 
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manufacturer suggests administrating high doses of trazodone in divided doses 
(Concordia International, 2016). An alternative to the administration of trazodone in 
divided doses during the day is the once daily administration of a MR formulation of 
trazodone (Fagiolini et al., 2012; Lemaire et al., 2009; Stahl, 2009). 
 
Dosing trazodone for insomnia 
Trazodone is used widely off-label in a low-dose as hypnotic for the treatment of sleep 
disorders (Stahl and Stahl, 2011). Trazodone’s short half-life is advantageous to treat 
insomnia, because its daytime sedation is minimal when trazodone is given only at 
night and at low doses, in agreement with the rapid decrease of the plasma and brain 
concentration curves for the single dose administration (Figures 3 and 4). 
 
Different studies were performed to determine the optimal dose of trazodone to treat 
insomnia. 
 
The first study in the respect was carried out by Muratorio and co-workers showing 
that low doses of trazodone (50 mg daily) were not effective as hypnotic in 4 non-
depressed patients whereas higher doses (> 250 mg daily) given to depressed patients 
helped the patients to sleep (Muratorio et al., 1974). In contrast, Karniol and co-
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workers showed that in 10 healthy volunteers were drowsier when taking a dose of 
0.33 mg/Kg (~ 25 mg daily considering an average weight of the patients of 70 Kg) 
rather than a dose of 0.57 mg/Kg (~ 50 mg daily) (Karniol et al., 1976). Both these 
previous studies should be interpreted carefully given the small number of patients 
involved. In contrast, another study involving 75 patients analysed the effect of dose 
on the treatment of insomnia associated with depression and concluded that a daily 
dosage of 50-100 mg (at night) improved sleep disorders, particularly when given at a 
dose of 100 mg (Mashiko et al., 1999). This finding was confirmed by another study in 
depressed insomniacs (Saletu-Zyhlarz et al., 2002). Recently Savarese and co-workers 
performed a retrospective cross-sectional study on 33 patients treated with trazodone 
given at different doses to treat insomnia for 3 months (Savarese et al., 2015) and 
reported that when patients were given a daily dose of 25-75 mg (at night) there were 
37.93% , 31.03% and 20.68% of responders when the night dose of trazodone was 25 
mg, 50 mg and 75 mg respectively.  When the dose was 100 mg or 150 mg daily at 
night, responder rates were only 10.43% and 0% respectively (Savarese et al., 2015). 
Taken together these studies show that a dose between 25mg and 100 mg seems to 
have a significant hypnotic effect that justifies the use of trazodone for insomnia at low 
doses.  
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Only one randomized parallel-group, double-blind study has been carried out for 
trazodone in non-depressed insomniacs.  This established the hypnotic efficacy of 
trazodone in comparison with zolpidem and placebo and concluded that trazodone 
given 50 mg daily for 2 weeks was an effective hypnotic for the short-term treatment 
of patients with primary insomnia, being only slightly less efficient than zolpidem 
(Walsh et al., 1998). Alongside these studies is the observation that the typical off-
licence hypnotic dose of trazodone in non-depressed patients is 50 mg at night.  We 
performed a PK simulation with such dose (50 mg daily) to better understand the 
pharmacological mechanism behind the hypnotic effect of trazodone. This dose 
afforded after approximately one hour following oral administration (Figure 3 and 4), a 
Cmax in the brain of 0.42 mg/L (Table 1). With this concentration, the predicted 
occupancy for SERT is 75%, whereas the serotonin receptors 1A,1D,2A and 2B  are 
expected to be more than 90% occupied.  5HT2C receptors are expected to show an 
occupancy of 83% whereas 5HT1B and 1E are expected to show and occupancy less 
than 10% (Table 3).  
 
The calculated occupancy for SERT is too low to achieve an antidepressant activity 
when a dose of 50 mg is given, since this transporter should be almost fully inhibited in 
order to exert a pharmacological action (Stahl, 2009). The hypnotic/anxiolytic effect at 
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low doses of trazodone can be understood by taking into account the occupancy 
predicted in our analyses as an antagonist for (i) 5-HT2A receptor (97%); (ii) alpha1A 
receptor (88%) and (iii) H1 receptor (84%).  The antagonism of each these receptors 
being known to cause an hypnotic effect (Stahl, 2009; Fagiolini et al., 2012). In 
addition, the activation of the 5-HT1A (91% occupancy as agonist/partial agonist) is 
likely to contribute to the anxiolytic effect of trazodone at these doses (Odagaki et al., 
2005).  
 
Less is known about the 5-HT1E receptor, however it has been proposed that it could 
regulate memory given that it is highly localised in the cortex, hippocampus, and 
olfactory bulb (Bai et al., 2004). The fact that trazodone does not block this receptor 
suggests that it could be used as hypnotic without affecting memory. This might 
suggest that trazodone can be safely prescribed in patients affected with dementia not 
least because trazodone does not to any extent block muscarinic receptors (table 3). A 
recent randomised double-blind and placebo-controlled study in AD patients 
confirmed in fact that trazodone (given with a dose of 50 mg at 10:00 PM for 2 weeks) 
was effective as hypnotic and did not have any effect on cognition using different 
rating scales (Camargos et al., 2014). 
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Dosing trazodone for depression 
Two clinical studies investigated the optimal dosing of trazodone for treating 
depression: Mukherjee and Davey compared the treatment of trazodone dosed as 25 
mg tds against 50 mg tds and reported the superiority of the latter dose regimen in 
treating this condition (Mukherjee and Davey, 1986).  Mihara and co-workers reported 
a significant linear relationship between the steady-state plasma concentration of 
trazodone and the percentage of patients improving depression as assessed by the 
Montgomery–Åsberg Depression Rating Scale (MADRS) (Mihara et al., 2002). 
 
Trazodone probably acts as antidepressant by different pharmacological mechanisms 
such as antagonism of the serotonin transporter (SERT), alpha-2 adrenoreceptor, 5-
HT2A and 5-HT2C receptors, as well as stimulation of the 5-HT1A (Stahl, 2009; Fagiolini et 
al., 2012).  
 
Drugs that block the re-uptake of serotonin increase the concentration of this 
neurotransmitter in the synaptic cleft. This is a well-known mechanism of action for 
the selective serotonin receptor inhibitors (SSRI): excess of serotonin in the synapse is 
thought to act on the post-synaptic 5-HT1A receptor providing antidepressant action 
(Stahl, 2009; Stahl, 2008).  SSRIs do not block post-synaptic 5-HT receptors and are 
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associated with side effects such as insomnia, anxiety and sexual dysfunction (Stahl, 
2008). Serotonin agonism on the 5HT2A and 5-HT2C post-synaptic receptors is the 
mechanism for this (Stahl, 2009; Stahl, 2008). The potential advantage of drugs such as 
trazodone is that, in addition to blocking SERT, trazodone is an antagonist at 5HT2A and 
5-HT2C receptors. 5-HT2C antagonism is observed with other drugs such as mirtazapine 
and agomelatine (Stahl, 2009; Stahl, 2008).  Each of these non-SSRI drugs are known to 
exert antidepressant activity with a much reduced risk of anxiety or sexual dysfunction. 
 
In addition to this, it has been postulated that simultaneous 5-HT2A and 5HT2C 
antagonism combined with SERT inhibition might also potentiate antidepressant effect 
and improve tolerability (Fagiolini et al., 2012; Stahl, 2009).  
 
As can be seen in Table 3 the occupancy for SERT is predicted to be 86% when 
trazodone is given as 100 mg daily and to 90% when trazodone is given as 150 mg 
daily. As expected, at these doses trazodone blocks almost completely the 5HT2A and 
5-HT2C receptors thus, in theory, reducing the risks of sexual dysfunction and anxiety 
related side-effects (Stahl, 2009).  The fact that high doses of trazodone are more 
effective in treating depression than low doses (Mukherjee and Davey, 1986; Mihara et 
al., 2002), suggests that the block of SERT (that is only significantly achieved when high 
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doses are given as explained above) is more important than the block of alpha-2 
adrenoreceptor, 5-HT2A and 5-HT2C receptors or the stimulation of the 5-HT1A 
receptor for treating depression. These receptors show a high occupancy at lower 
doses (Table 3). 
 
Different studies report that trazodone usually decreases REM sleep (Aton et al., 2009) 
(Brogden et al., 1981) (Mendelson, 2005) (Yamatsu et al., 1974; van Bemmel et al., 
1992). However, to our knowledge only one study investigated the effect of the dose 
of trazodone to the amount of rapid eye movement (REM) during sleep following 
administration of this drug (Yamatsu et al., 1974).  According to this investigation the 
suppression of REM is proportional to the dose of trazodone administered (Yamatsu et 
al., 1974). We suggest that this could be correlated to the fact that at high doses of 
trazodone, the increased concentration of serotonin in the synaptic cleft (as a result of 
SERT-block) activates 5-HT1B receptors. The agonist activation of this receptor has been 
shown to decrease REM during sleep (Boutrel et al., 1999): the fact that trazodone 
does not block this receptor (Table 3) could explain the fact that when serotonin 
concentration increases following SERT block by high doses of trazodone,  the effect is 
a suppression of REM and this hypothesis would be confirmed by the trazodone’s 
dose-dependent suppression of REM. These findings support the fact that low doses of 
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trazodone (typically 50 mg at night) should be preferred for treating insomnia, since 
the quality of sleep would be improved given that REM phases would not be majorly 
affected. 
 
Dosing trazodone for possible neuroprotection in humans 
Halliday and co-workers recently proposed a possible beneficial use of trazodone in 
dementia and AD by showing that this drug is able to reverse unfolded protein 
response (UPR)/integrated stress response (ISR) activation induced by UPR stressors 
such as tunicamycin. The authors showed in particular that trazodone was able to 
reduce the levels of activating transcription factor 4 (ATF4) without affecting the level 
of phosphorylated eukaryotic initiation factor 2α (eIF2α-P) (Halliday et al., 2017).  
However, the authors of this study did not explain the mechanism by which trazodone 
produced this effect. Given that it has been showed that p38 activates the expression 
of ATF4 in tunicamycin-induced endoplasmic reticulum stress-related 
PERK/eIF2α/ATF4 pathway (Jiang et al., 2014) and  also that  5-HT2A agonism activates 
the mitogen-activated protein kinase p38 (Kurrasch-Orbaugh et al., 2003), it is evident 
that trazodone’s antagonist activity on the 5-HT2A receptor is expected to decrease the 
activity of p38 and this should decrease also the formation of ATF-4. Thus we suggest 
that 5-HT2A blockade could have a protective role against dementia and AD and explain 
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the effects described in the recent study (Halliday et al., 2017). Our hypothesis has 
been also confirmed by the fact that there is partial reduction of neuro-protective 
effect in presence of the 5-HT2A receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-
2-aminopropane (R-DOI) (Daniele et al., 2015). The latter ligand displays a high affinity 
towards 5-HT2A (K1=3.36 nM) (Knight et al., 2004), approximately 10- fold stronger 
than the affinity of trazodone for the same receptor. In addition, the decreased activity 
of p38 as result of 5-HT2A block is expected to decrease the expression of nuclear 
factor kappa B (NF-kappa B), that is an important transcription factor in inflammation 
(Olson et al., 2007). Moreover, trazodone is expected to have beneficial towards 
dementia and AD because, as a 5-HT1A agonist it is expected to lead to ERK1/2 
activation that is known to increase the protein expression of brain-derived 
neurotrophic factor (Polter and Li, 2010; Masson et al., 2012; Daniele et al., 2015). Also 
the block of H1 and alpha-1 receptors are both expected to decrease the expression of 
NF-kappa B (Bakker et al., 2001; Gupta et al., 2009; Perez et al., 2009) 
 
Given that 5-HT1, 5-HT2A, H1 and alpha1 receptors are saturated with a dose of 50 mg 
daily (Table 3), our study suggests that this dose might suffice for observing neuro-
protective effects towards dementia/AD and we suggest that it will be reasonable to 
use this dose for future clinical studies of trazodone in dementia/AD.  
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Rationale for the presence of unanticipated side effects of trazodone 
The fact that trazodone displays minimal central or peripheral occupancy for 
muscarinic receptors at these doses makes this drug suitable for treating patients with 
glaucoma, angina, prostatism, constipation, and dementia. 
 
The central occupancy of the receptors calculated in our study can also be used to 
understand the side-effects reported by patients taking trazodone. In particular, we 
explain how the occupancy for the different receptors for trazodone can explain three 
peculiar side effects of trazodone (i) hypo-salivation; (ii) hypotension; (iii) priapism.  
 
It is clear from Table 3 that trazodone does not block the muscarinic receptor, thus 
hyposalivation is not mediated by antagonism of acetylcholine. Lung and colleagues 
reported that salivation is also controlled by alpha receptors: in particular 
hypersalivation can be caused by alpha 1-agonists and/or alpha-2 antagonists, whereas 
hypo-salivation is caused by alpha 1 antagonists and/or alpha 2 agonists (Lung, 1994). 
This is also supported by one of the theories according to which the clozapine-induced 
hypersalivation is mediated by the block of the alpha-2 adrenergic receptors (Corrigan 
et al., 1995; Szabadi, 1996).  The binding data reported in Table 2 show that trazodone 
has a stronger affinity for the alpha-1A receptor than the alpha-2 receptors (153 nM 
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and 441.5 nM (average value of the affinity for the alpha2C and alpha2A receptors) 
respectively). This is also reflected with the occupancy (Table 4). This binding profile 
could therefore explain why trazodone can cause hypo-salivation (dry mouth).  
 
A relatively frequent side effect of trazodone is hypotension. The specific binding 
profile of trazodone in respect to alpha receptors can also help to explain this side 
effect. It is known that alpha-1 agonists and alpha-2 blockers cause hypertension 
whereas alpha-1 antagonists and alpha-2 agonists cause hypotension (Reid, 1986). 
Using a similar reasoning to provide the explanation for the hyposalivation, the fact 
that the block of alpha-1 receptor is stronger than alpha-2 receptor can also explain 
the hypotension sometimes seen with trazodone. 
 
There have been several reports of priapism associated with the use of trazodone 
(Hayes and Kristoff, 1986). Our study agrees with published studies that proposed that 
the effect is related to blockade of alpha-receptors in the absence of sufficient 
antimuscarinic activity (Patel et al., 1996).  This criteria is fulfilled by the 
pharmacological profile of trazodone. Notably yohimbine blocks the alpha-2 receptors 
and has been studied for potential treatment for erectile dysfunction (Andersson and 
Stief, 2001). 
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Conclusion  
In this study we have validated the use of BM for PK simulations as we were able to 
reproduce PK simulations of trazodone published in the literature. We have shed some 
more light on the mechanism of action of trazodone in the treatment of different 
conditions (depression, insomnia and a possible use as protective treatment for 
dementia/AD). Our study indicates that low doses (typically of 50 mg daily) should be 
used for treating insomnia and such doses will have a minimal influence on REM sleep, 
and possibly to further investigates a pharmacological protection of trazodone for 
neurodegenerative conditions such as dementia/AD.  
 
Our findings are corroborated by the prediction of brain concentrations of trazodone 
using different drug dosing regimens and the prediction of occupancy for 28 different 
targets for which published trazodone binding data are available. The occupancy of 
specific receptors is also able to explain the rational for the presence of specific side 
effects reported for trazodone. 
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